Clicky

Novo Nordisk A/S Class B(0QIU)

Description: Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.


Keywords:

Home Page: www.novonordisk.com

0QIU Technical Analysis

Novo Allé 1
Bagsvaerd, 2880
Denmark
Phone: 45 44 44 88 88


Officers

Name Title
Mr. Lars Fruergaard Jorgensen Pres, CEO & Member of Management Board
Mr. Karsten Munk Knudsen Exec. VP, CFO & Member of the Management Board
Mr. Henrik Ehlers Wulff Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board
Ms. Camilla Sylvest Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board
Dr. Martin Holst Lange Exec. VP, Head of Devel. & Member of the Management Board
Ms. Monique Carter Exec. VP, Head of People & Organisation and Member of Management Board
Dr. Marcus Schindler Ph.D. EVP, Head of Research & Early Devel., Chief Scientific Officer & Member of the Management Board
Mr. Maziar Mike Doustdar Exec. VP, Head of International Operations & Member of the Management Board
Mr. Douglas J. Langa Exec. VP, Head of North America Operations & Member of Management Board
Mr. Ludovic Helfgott Exec. VP, Head of Rare Disease & Member of Management Board

Exchange: LSE

Country: GB : United Kingdom of Great Britain and Northern Ireland

Currency: Danish krone (kr)

Forward PE: 0
Trailing PE: 0.3896
Price-to-Book MRQ: 0
Price-to-Sales TTM: 0.119
IPO Date:
Fiscal Year End: December
Full Time Employees: 59337
Back to stocks